Asset Details
Do you wish to reserve the book?
Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
Do you wish to request the book?
Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Randomized Double-Blind Placebo-Controlled Trial of Lithium in Youths with Severe Mood Dysregulation
2009
Overview
Objective:
The diagnosis and treatment of youth with severe nonepisodic irritability and hyperarousal, a syndrome defined as severe mood dysregulation (SMD) by Leibenluft, has been the focus of increasing concern. We conducted the first randomized double-blind, placebo-controlled trial in SMD youth, choosing lithium on the basis of its potential in treating irritability and aggression and neuro-metabolic effects.
Methods:
SMD youths 7–17 years were tapered off their medications. Those who continued to meet SMD criteria after a 2-week, single-blind, placebo run-in were randomized to a 6-week double-blind trial of either lithium (n = 14) or placebo (n = 11). Clinical outcome measures were: (1) Clinical Global Impressions–Improvement (CGI-I) score less than 4 at trial's end and (2) the Positive and Negative Syndrome Scale (PANSS) factor 4 score. Magnetic resonance spectroscopy (MRS) outcome measures were myoinositol (mI), N-acetyl-aspartate (NAA), and combined glutamate/glutamine (GLX), all referenced to creatine (Cr).
Results:
In all, 45% (n = 20/45) of SMD youths were not randomized due to significant clinical improvement during the placebo run-in. Among randomized patients, there were no significant between-group differences in either clinical or MRS outcome measures.
Conclusion:
Our study suggests that although lithium may not result in significant clinical or neurometabolic alterations in SMD youths, further SMD treatment trials are warranted given its prevalence.
Publisher
SAGE Publications,Mary Ann Liebert, Inc
Subject
/ Antimanic Agents - administration & dosage
/ Antimanic Agents - therapeutic use
/ Aspartic Acid - analogs & derivatives
/ Attention Deficit Disorder with Hyperactivity - diagnosis
/ Attention Deficit Disorder with Hyperactivity - drug therapy
/ Attention Deficit Disorder with Hyperactivity - physiopathology
/ Attention Deficit Disorder with Hyperactivity - psychology
/ Bipolar Disorder - diagnosis
/ Bipolar Disorder - drug therapy
/ Bipolar Disorder - physiopathology
/ Bipolar Disorder - psychology
/ Child
/ Female
/ Humans
/ Lithium
/ Lithium Carbonate - administration & dosage
/ Lithium Carbonate - therapeutic use
/ Magnetic Resonance Spectroscopy
/ Male
/ Mood Disorders - drug therapy
